ZAI LAB LIMITED APIC, Share-based Payment Arrangement, Increase for Cost Recognition
ZAI LAB LIMITED (ZLAB) reported APIC, Share-based Payment Arrangement, Increase for Cost Recognition of $11.94 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue · last filed 2026-08-06
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-06-30 was $11.94M, a 29.65% decline year-over-year.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2026-03-31 was $13.52M, a 14.41% decline year-over-year.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-09-30 was $16.92M, a 0.76% increase year-over-year.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for the quarter ending 2025-06-30 was $16.97M, a 8.93% decline year-over-year.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2025 was $65.60M, a 7.15% decline from fiscal 2024.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2024 was $70.65M, a 11.28% decline from fiscal 2023.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2023 was $79.63M, a 29.90% increase from fiscal 2022.
- ZAI LAB LIMITED apic, share-based payment arrangement, increase for cost recognition for fiscal 2022 was $61.30M, a 50.57% increase from fiscal 2021.
| Period end | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 3 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 6 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 9 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month | APIC, Share-based Payment Arrangement, Increase for Cost Recognition 12 month as first filed |
|---|---|---|---|---|---|
| 2026-06-30 | $11.94M 10-Q · filed 2026-08-06 | $25.46M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2026-03-31 | $13.52M 10-Q · filed 2026-08-06 | ||||
| 2025-12-31 | $65.60M 10-K · filed 2026-02-26 | ||||
| 2025-09-30 | $16.92M 10-Q · filed 2025-11-06 | $33.90M derived: sum of 2 quarters · filed 2026-08-06 | $49.70M derived: sum of 3 quarters · filed 2026-08-06 | ||
| 2025-06-30 | $16.97M 10-Q · filed 2026-08-06 | $32.77M derived: sum of 2 quarters · filed 2026-08-06 | |||
| 2025-03-31 | $15.80M 10-Q · filed 2026-08-06 | ||||
| 2024-12-31 | $70.65M 10-K · filed 2026-02-26 | ||||
| 2024-09-30 | $16.80M 10-Q · filed 2025-11-06 | $35.43M derived: sum of 2 quarters · filed 2025-11-06 | $53.41M derived: sum of 3 quarters · filed 2025-11-06 | ||
| 2024-06-30 | $18.64M 10-Q · filed 2025-11-06 | $36.62M derived: sum of 2 quarters · filed 2025-11-06 | |||
| 2024-03-31 | $17.98M 10-Q · filed 2025-11-06 | ||||
| 2023-12-31 | $79.63M 10-K · filed 2026-02-26 | ||||
| 2023-09-30 | $21.99M 10-Q · filed 2024-11-12 | $42.50M derived: sum of 2 quarters · filed 2024-11-12 | $59.16M derived: sum of 3 quarters · filed 2024-11-12 | ||
| 2023-06-30 | $20.51M 10-Q · filed 2024-11-12 | $37.17M derived: sum of 2 quarters · filed 2024-11-12 | |||
| 2023-03-31 | $16.66M 10-Q · filed 2024-11-12 | ||||
| 2022-12-31 | $61.30M 10-K · filed 2025-02-27 | ||||
| 2022-09-30 | $19.11M 10-Q · filed 2023-11-07 | $33.33M derived: sum of 2 quarters · filed 2023-11-07 | $45.74M derived: sum of 3 quarters · filed 2023-11-07 | ||
| 2022-06-30 | $14.22M 10-Q · filed 2023-11-07 | $26.64M derived: sum of 2 quarters · filed 2023-11-07 | |||
| 2022-03-31 | $12.41M 10-Q · filed 2023-11-07 | ||||
| 2021-12-31 | $40.71M 10-K · filed 2024-02-27 | ||||
| 2021-09-30 | $10.56M 10-Q · filed 2022-11-09 | $20.79M derived: sum of 2 quarters · filed 2022-11-09 | $28.11M derived: sum of 3 quarters · filed 2022-11-09 | ||
| 2021-06-30 | $10.23M 10-Q · filed 2022-11-09 | $17.55M derived: sum of 2 quarters · filed 2022-11-09 | |||
| 2021-03-31 | $7.32M 10-Q · filed 2022-11-09 | ||||
| 2020-12-31 | $24.83M 10-K · filed 2023-03-01 | ||||
| 2020-09-30 | $6.98M 10-Q · filed 2021-11-09 | $13.94M derived: sum of 2 quarters · filed 2021-11-09 | $20.41M derived: sum of 3 quarters · filed 2021-11-09 | $26.14M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-06-30 | $6.96M 10-Q · filed 2021-11-09 | $13.43M 6-K · filed 2020-09-11 | $19.16M derived: sum of 3 quarters · filed 2022-03-01 | $24.42M derived: sum of 4 quarters · filed 2022-03-01 | |
| 2020-03-31 | $6.46M 10-Q · filed 2021-11-09 | $12.20M derived: sum of 2 quarters · filed 2022-03-01 | $17.46M derived: sum of 3 quarters · filed 2022-03-01 | ||
| 2019-12-31 | $5.74M derived: 10-K 12 month − 6-K 9 month · filed 2022-03-01 | $11.00M derived: sum of 2 quarters · filed 2022-03-01 | $20.29M 10-K · filed 2022-03-01 | ||
| 2019-09-30 | $5.26M derived: 6-K 9 month − 6-K 6 month · filed 2020-01-21 | $14.55M 6-K · filed 2020-01-21 | |||
| 2019-06-30 | $9.29M 6-K · filed 2020-09-11 | ||||
| 2018-12-31 | $4.23M derived: 10-K 12 month − 6-K 9 month · filed 2021-03-01 | $12.23M 10-K · filed 2021-03-01 | $12.23M 20-F · filed 2019-03-29 | ||
| 2018-09-30 | $8.00M 6-K · filed 2020-01-21 | ||||
| 2017-12-31 | $9.93M 20-F · filed 2020-04-29 | $9.93M 20-F · filed 2018-04-30 | |||
| 2016-12-31 | $4.93M 20-F · filed 2019-03-29 | ||||
| 2015-12-31 | $2.70M 20-F · filed 2018-04-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Viridian Therapeutics, Inc.\DE (VRDN) | United States | $2.342B | -5.38 |
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Bausch Health Companies Inc. (BHC) | $2.113B | -1.68 | |
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |